NewLink Genetics initiates Phase I renal cell cancer trial

NewLink Genetics Corporation, a biopharmaceutical company, has initiated a first in human Phase I clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.01/07/2014

Source: Kidney Cancer Association - January 7, 2014 Category: Cancer & Oncology Source Type: news